[Craig Nigrelli]

G-L-P-1 DRUGS ARE RESHAPING THE WAY AMERICANS LOOK AT WEIGHT LOSS NOW THAT A FEW OF THEM HAVE BEEN APPROVED BY THE F-D-A TO HELP BATTLE OBESITY… AND A NEW STUDY IS SHEDDING LIGHT ON TWO OF THE MOST POPULAR DRUGS PEOPLE TURN TO TO HELP THEM SEHD POUNDS.

IN THE FIRST HEAD-TO-HEAD RANDOMIZED CLINICAL TRIAL OF THESE DRUGS, RESEARCHERS COMPARED RESULTS FROM ELI LILLY’S ZEPBOUND AND NOVO NORDISK’S WEGOVY.

IT IS IMPORTANT TO NOTE THE STUDY WAS FUNDED BY ELI LILLY.

PREVIOUS STUDIES HAVE SHOWN ZEPBOUND HELPED PEOPLE LOSE MORE WEIGHT THAN WEGOVY… BUT THEY’RE NOT CONSIDERED TRUE COMPARISONS OF THE DRUGS BECAUSE THE RESULTS WERE BASED OF PRE-EXISTING DATA.

THIS **NEW** TRIAL HAD PEOPLE WHO WERE OVERWEIGHT OR OBESE USE THE DRUGS ONCE A WEEK FOR 72 WEEKS…

AND FOUND WHO WERE INJECTED WITH ZEPBOUND LOST ABOUT 20 PERCENT OF THEIR BODY WEIGHT –

OR AN AVERAGE OF AT LEAST 50 POUNDS…

WHILE THOSE WHO GOT WEGOVY LOST AN AVERAGE OV A LITTLE MORE THAN 13 PERCENT OF THEIR BODY WEIGHT…

OR AROUND 33 POUNDS.

ELI LILLY SAYS THAT MEANS ZEPBOUND IS NEARLY TWICE AS EFFECTIVE AS WEGOVY.

DOCTORS SAY DESPITE THE DIFFERENCE IN RESULTS – BOTH DRUGS ARE STILL HIGHLY EFFECTIVE AT HELPING PEOPLE LOSE WEIGHT.

AND IN A STATEMENT, A NOVO NORDISK SPOKESPERSON NOTED WEGOVY HAD BEEN LINKED TO A REDUCED RISK OF HEART ISSUES – LIKE HEART ATTACK AND STROKE.

ANOTHER THING TO NOTE IS ASIDE FROM THEIR NAMES – ZEPBOUND AND WEGOVY ARE DIFFERENT IN ANOTHER IMPORTANT WAY: THEIR ACTIVE INGREDIENTS.

ZEPBOUND USES TIRZEPATIDE TO HELP YOU LOSE WEIGHT, WHILE WEGOVY IS A SEMAGLUTIDE INJECTION.

BOTH TARGET G-L-P-1 RECEPTORS TO MAKE YOU FEEL LESS HUNGRY… BUT UNLIKE SEMAGLUTIDE – TIRZEPATIDE **ALSO** TARGETS WHAT ARE CALLED G-I-P RECEPTORS, WHICH TENDS TO REDUCE A PERSON’S APPETITE MORE THAN JUST A G-L-P-1 DRUG ALONE.